Recombinant, refolded tetrameric p53 and gonadotropin-releasing hormone-p53 slow proliferation and induce apoptosis in p53-deficient cancer cells

Molecular Cancer Therapeutics

Volumn 7, Issue 6, 2008, Pages 1420-1429

  Lafevre Bernt, Michelle ^a   Wu, Shili ^a   Lin, Xinli ^a,b  

^a ProteomTech Inc   (United States)

^b GeneCopoeia Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN; HYBRID PROTEIN; PROTEIN P53; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTERNALIZATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FOLDING; BIOASSAY; CHEMISTRY; ENDOCYTOSIS; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; METABOLISM; NEOPLASM; NICK END LABELING; NUCLEOSOME; PATHOLOGY; PROTEIN QUATERNARY STRUCTURE; PROTEIN TRANSPORT; THERMODYNAMICS; TUMOR CELL LINE;

APOPTOSIS; BIOLOGICAL ASSAY; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOCYTOSIS; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; NEOPLASMS; NUCLEOSOMES; PROTEIN FOLDING; PROTEIN STRUCTURE, QUATERNARY; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS; THERMODYNAMICS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 49849100270     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0078     Document Type: Article

References (50)

1. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004;4:793-805.
2. Braithwaite AW, Royds JA, Jackson P. The p53 story: layers of complexity. Carcinogenesis 2005;26:1161-9.
3. Coutts AS, La Thangue NB. The p53 response: emerging levels of co-factor complexity. Biochem Biophys Res Commun 2005;331:778-85.
4. Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358:15-6.
5. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
6. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-14.
7. Malkin D. Germline p53 mutations and heritable cancer. Annu Rev Genet 1994;28:443-65.
8. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006;127:1323-34.
9. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007;445:661-5.
10. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445:656-60.
11. Teodoro JG, Parker AE, Zhu X, Green MR. p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 2006;313:968-71.
12. Lomas M, Liauw W, Packham D, et al. Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy. Ann Oncol 2004;15:324-9.
13. Deng H, Kowalczyk D, O I, et al. A modified DNA vaccine to p53 induces protective immunity to challenge with a chemically induced sarcoma cell line. Cell Immunol 2002;215:20-31.
14. Vassilev LT. p53 activation by small molecules: application in oncology. J Med Chem 2005;48:4491-9.
15. Kosakowska-Cholody T, Cholody WM, Monks A, Woynarowska BA, Michejda CJ. WMC-79, a potent agent against colon cancers, induces apoptosis through a p53-dependent pathway. Mol Cancer Ther 2005;4:1617-27.
16. Snyder EL, Meade BR, Saenz CC, Dowdy SF. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol 2004;2:E 36.
17. D'Orazi G, Marchetti A, Crescenzi M, Coen S, Sacchi A, Soddu S. Exogenous wt-p53 protein is active in transformed cells but not in their non-transformed counterparts: implications for cancer gene therapy without tumor targeting. J Gene Med 2000;2:11-21.
18. Zeimet AG, Marth C. Why did p53 gene therapy failin ovarian cancer? Lancet Oncol 2003;4:415-22.
19. McLure KG, Lee PW. How p53 binds DNA as a tetramer. EMBO J 1998;17:3342-50.
20. Nie Y, Li HH, Bula CM, Liu X. Stimulation of p53 DNA binding by c-Abl requires the p53 C terminus and tetramerization. Mol Cell Biol 2000;20:741-8.
21. Liu X, Miller CW, Koeffler PH, Berk AJ. The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol Cell Biol 1993;13:3291-300.
22. Marston NJ, Jenkins JR, Vousden KH. Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6. Oncogene 1995;10:1709-15.
23. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 2000;14:289-300.
24. Chene P. Fast, qualitative analysis of p53 phosphorylation by protein kinases. Biotechniques 2000;28:240-2.
25. Kubbutat MH, Ludwig RL, Ashcroft M, Vousden KH. Regulation of Mdm2-directed degradation by the C terminus of p53. Mol Cell Biol 1998;18:5690-8.
26. Maki CG. Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J Biol Chem 1999;274:16531-5.
27. Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, Wahl GM. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 1999;18:1660-72.
28. Kim YT, Downs D, Wu S, et al. Enzymic properties of recombinant BACE2. Eur J Biochem 2002;269:5668-77.
29. Lin XL, Lin YZ, Tang J. Relationships of human immunodeficiency virus protease with eukaryotic aspartic proteases. Methods Enzymol 1994;241:195-224.
30. Lin X. Universal procedure for refolding recombinant proteins. US patent 6,583,268. 2003.
31. Friedman PN, Chen X, Bargonetti J, Prives C. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc Natl Acad Sci U S A 1993;90:3319-23.
32. Sun XZ, Vinci C, Makmura L, et al. Formation of disulfide bond in p53 correlates with inhibition of DNA binding and tetramerization. Antioxid Redox Signal 2003;5:655-65.
33. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001;19:117 3-6.
34. Amundson SA, Do KT, Vinikoor L, et al. Stress-specific signatures: expression profiling of p53 wild-type and -null human cells. Oncogene 2005;24:4572-9.
35. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8.
36. Wang P, Reed M, Wang Y, et al. p53 domains: structure, oligomerization, and transformation. Mol Cell Biol 1994;14:5182-91.
37. Ho WC, Fitzgerald MX, Marmorstein R. Structure of the p53 core domain dimer bound to DNA. J Biol Chem 2006;281:20494-502.
38. Lee KO, Luu N, Kaneski CR, Schiffmann R, Brady RO, Murray GJ. Improved intracellular delivery of glucocerebrosidase mediated by the HIV-1 TAT protein transduction domain. Biochem Biophys Res Commun 2005;337:701-7.
39. King JA, Millar RP. Evolutionary aspects of gonadotropin-releasing hormone and its receptor. Cell Mol Neurobiol 1995;15:5-23.
40. Sealfon SC, Weinstein H, Millar RP. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev 1997;18:180-205.
41. Schally AV, Comaru-Schally AM, Nagy A, et al. Hypothalamic hormones and cancer. Front Neuroendocrinol 2001;22:248-91.
42. Ben-Yehudah A, Lorberboum-Galski H. Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteins. Expert Rev Anticancer Ther 2004;4:151-61.
43. Nechushtan A, Yarkoni S, Marianovsky I, Lorberboum-Galski H. Adenocarcinoma cells are targeted by the new GnRH-PE66 chimeric toxin through specific gonadotropin-releasing hormone binding sites. J Biol Chem 1997;272:11597-603.
44. Schlick J, Dulieu P, Desvoyes B, Adami P, Radom J, Jouvenot M. Cytotoxic activity of a recombinant GnRH-PAP fusion toxin on human tumor cell lines. FEBS Lett 2000;472:241-6.
45. Azar Y, Lorberboum-Galski H. GnRH-Bik/Bax/Bak chimeric proteins target and kill adenocarcinoma cells; the general use of pro-apoptotic proteins of the Bcl-2 family as novel killing components of targeting chimeric proteins. Apoptosis 2000;5:531-42.
46. Ben-Yehudah A, Aqeilan R, Robashkevich D, Lorberboum-Galski H. Using apoptosis for targeted cancer therapy by a new gonadotropin releasing hormone-DNA fragmentation factor 40 chimeric protein. Clin Cancer Res 2003;9:1179-90.
47. Weisbart RH, Miller CW, Chan G, Wakelin R, Ferreri K, Koeffler HP. Nuclear delivery of p53 C-terminal peptides into cancer cells using scFv fragments of a monoclonal antibody that penetrates living cells. Cancer Lett 2003;195:211-9.
48. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004;10:310-5.
49. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviralp53, INGN 101, p53 gene therapy - Introgen, RPR/INGN 201. BioDrugs 2003;17:216-22.
50. Skehel JJ, Cross K, Steinhauer D, Wiley DC. Influenza fusion peptides. Biochem Soc Trans 2001;29:623-6.